Page last updated: 2024-08-24

topotecan and volasertib

topotecan has been researched along with volasertib in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ	1
Brabetz, S; Chan, JA; Herold-Mende, C; Kool, M; Korshunov, A; Mack, N; Milde, T; Pfister, SM; Schmidt, C; Schubert, NA; Schwalm, B; Selt, F; Witt, O	1

Other Studies

2 other study(ies) available for topotecan and volasertib

Article	Year
Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15 Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship	2013
Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients. Neuro-oncology, 2017, Nov-29, Volume: 19, Issue:12 Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Proliferation; Child, Preschool; Dactinomycin; Female; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms, Germ Cell and Embryonal; Neuroectodermal Tumors, Primitive; Pteridines; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2017

Article

Year

Identification of potent Yes1 kinase inhibitors using a library screening approach.

Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013

Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients.

Neuro-oncology, 2017, Nov-29, Volume: 19, Issue:12

Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Proliferation; Child, Preschool; Dactinomycin; Female; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms, Germ Cell and Embryonal; Neuroectodermal Tumors, Primitive; Pteridines; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2017